Clinical Trial Search

Phase 3 N=246 A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters

Dysfunctional Central Venous Access Catheters

Primary: Percentage of Patients Who Had Cumulative Restoration Rates of Central Venous Catheter (CVC) Function Following a Single Administration of Tenecteplase — 72.0 percentage…

Genentech, Inc. Results Apr 2011 2.4% serious AE View details

Phase 3 N=397 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.

Infections, Papillomavirus · Papillomavirus Vaccines

Primary: Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values. — 353; 358 Subjects

GlaxoSmithKline Results Apr 2011 2.6% serious AE View details

Phase 3 N=155 Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

Asthma

Primary: The Number of Participants With Confirmed Positive Human Antihuman Antibody (HAHA) Results at the End of the 16-week Follow-up Period — 0; 0; 0; 0 participants

Novartis Results Apr 2011 5.0% serious AE View details

Phase 3 N=90 Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy

Hypertension; Hypertrophy, Left Ventricular

Primary: Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI) — -7.1; -9.1 g/m˄2

Novartis Results Apr 2011 8.9% serious AE View details

Phase 3 N=498 Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Lymphoblastic Leukemia, Acute

Primary: Overall Event-free Survival (EFS) — 87.3 Percentage of Participants

St. Jude Children's Research Hospital Results Apr 2011 14.9% serious AE View details

Phase 3 N=4,150 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

HIV Infections

Primary: New or Recurrent HIV Disease Progression Event Including Death — 159; 165 participants — p=.55

National Institute of Allergy and Infectious… Results Apr 2011 20.7% serious AE View details

Phase 3 N=164 International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

Cystic Fibrosis

Primary: Change in CFQ-R Respiratory Symptoms Scale (RSS) Score — -2.63; 7.08 units on a scale — p=0.0005

Gilead Sciences Results Apr 2011 10.4% serious AE View details

Phase 3 N=598 Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

Varicella

Primary: Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process). — 96.3 Percent of participants

Merck Sharp & Dohme LLC Results Apr 2011 0.3% serious AE View details

Phase 3 N=1,029 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis

Onychomycosis

Primary: Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks — 1.18; 0.96 Percentage of participants

Novartis Results Apr 2011 2.7% serious AE View details

Phase 3 N=518 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

Onychomycosis

Primary: Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks. — 0.79; 0.78; 1.47; 0.00 Percentage of Participants

Novartis Pharmaceuticals Results Apr 2011 3.9% serious AE View details

Phase 3 N=412 Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Osteoporosis

Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 — 7.51; 4.37; 7.05 Percent change

Novartis Results Apr 2011 11.7% serious AE View details

Phase 3 N=68 Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

Diabetes Mellitus, Non-Insulin-Dependent

Primary: Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24

Merck Sharp & Dohme LLC Results Apr 2011 0.0% serious AE View details

Phase 3 N=2,456 Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

Osteoporosis

Primary: Percentage Change in Bone Mineral Density (BMD) of Femoral Neck at Year 6 Relative to Year 3 — 0.557; -0.493; 3.337 Percentage Change in BMD

Novartis Results Apr 2011 26.8% serious AE View details

Phase 3 N=551 Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

Hypertension

Primary: Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. — -31.72; -31.30; -15.85 mmHg — p=<0.001

Takeda Results Apr 2011 1.3% serious AE View details

Phase 3 N=1,275 Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

Primary: Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring. — -12.15; -13.48; -14.62; -12.56 mmHg — p=<0.001

Takeda Results Apr 2011 1.1% serious AE View details